Edition:
United States

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

82.48CHF
11:13am EDT
Change (% chg)

CHF0.48 (+0.59%)
Prev Close
CHF82.00
Open
CHF81.70
Day's High
CHF82.50
Day's Low
CHF81.58
Volume
1,826,510
Avg. Vol
4,394,450
52-wk High
CHF88.30
52-wk Low
CHF71.84

Select another date:

Fri, Oct 12 2018

Photo

Abbvie settles Humira patent disputes with Novartis unit

Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira.

Abbvie settles Humira patent disputes with Novartis unit

Oct 11 Abbvie Inc said on Thursday it settled all patent disputes with Novartis AG, granting it a non-exclusive license to manufacture and sell a copycat version of blockbuster drug, Humira.

BRIEF-Novartis Announces Data From Trial To Show Superior Efficacy Of Gilenya Over Copaxone In Patients With Relapsing Remitting Multiple Sclerosis

* NOVARTIS ANNOUNCES NEW DATA FROM THE FIRST DIRECT HEAD-TO-HEAD TRIAL TO DEMONSTRATE SUPERIOR EFFICACY OF GILENYA® OVER COPAXONE® IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS

BRIEF-Novartis seeks U.S., EU regulatory approval for MS drug Siponimod

* NOVARTIS ANNOUNCES FDA AND EMA FILING ACCEPTANCE OF SIPONIMOD, THE FIRST AND ONLY DRUG SHOWN TO MEANINGFULLY DELAY DISABILITY PROGRESSION IN TYPICAL SPMS PATIENTS

BRIEF-Novartis licenses three anti-infective programnes to Boston Pharmaceuticals

* NOVARTIS LICENSES THREE NOVEL ANTI-INFECTIVE PROGRAMS TO BOSTON PHARMACEUTICALS

Novartis strikes deal with Chinese firm to make Kymriah

ZURICH Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

UPDATE 1-Novartis strikes deal with Chinese firm to make Kymriah

ZURICH, Sept 27 Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country. Local regulations require that Novartis manufactures Kymriah in China if it wants to treat the country's patients with the drug.

Novartis strikes deal with Chinese firm to make Kymriah

ZURICH, Sept 27 Novartis has enlisted Chinese manufacturer Cellular Biomedicine (CBMG) to make its $475,000 gene-modifying cancer treatment Kymriah as the Swiss drugmaker intends to win approval for the therapy in the world's most populous country.

BRIEF-Cellular Biomedicine Group Enters Into Strategic Licensing And Collaboration Agreement With A Global Leader In Car-T Cell Therapy For Patients In China

* CELLULAR BIOMEDICINE GROUP ENTERS INTO STRATEGIC LICENSING AND COLLABORATION AGREEMENT WITH A GLOBAL LEADER IN CAR-T CELL THERAPY FOR PATIENTS IN CHINA

BRIEF-Novartis Proposes To Exit Grimsby UK Site By End Of 2020

* NOVARTIS PROPOSES TO EXIT GRIMSBY UK SITE BY END OF 2020 AS PART OF GLOBAL MANUFACTURING NETWORK TRANSFORMATION

Select another date: